Clinical significance of matrix metalloproteinase-9 expression in esophageal squamous cell carcinoma

World Journal of Gastroenterology

Volumn 11, Issue 6, 2005, Pages 871-874

  Gu, Zhen Dong ^a   Chen, Ke Neng ^a   Li, Ming ^a   Gu, Jin ^a   Li, Ji You ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Biomarker; Clinicopathological parameters; Esophageal squamous cell carcinoma; Immunohistochemistry; Matrix metalloproteinase 9

Indexed keywords

BIOLOGICAL MARKER; GELATINASE B;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER INVASION; CELL DIFFERENTIATION; CELL MEMBRANE PERMEABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DIAGNOSTIC PROCEDURE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STROMA CELL;

EID: 14544286833     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i6.871     Document Type: Article

References (21)

1. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516
2. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seike M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61-65
3. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets. Int J Cancer 2002; 99: 157-166
4. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996; 2: 461-462
5. Talvensaari-Mattila A, Paakko P, Hoyhtya M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein: A marker of aggressiveness in breast carcinoma. Cancer 1998; 83: 1153-1162
6. Fong KM, Kida Y, Zimmerman PV, Smith PJ. TIMP1 and adverse prognosis in non-small cell lung cancer. Clin Cancer Res 1996; 2: 1369-1372
7. Chen JQ, Zhan WH, He YL, Peng JS, Wang JP, Cai SR, Ma JP. Expression of heparanase gene, CD44v6, MMP-7 and nm23 protein and their relationship with the invasion and metastasis of gastric carcinomas. World J Gastroenterol 2004; 10: 776-782
8. Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, van Krieken JH, Lamers CB, Verspaget HW. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996; 74: 413-417
9. Ohashi K, Nemoto T, Nakamura K, Nemori R. Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinoma. Cancer 2000; 88: 2201-2209
10. Chen KN, Xu GW. The diagnosis and treatment for esophageal cancer. Shijie Huaren Xiaohua Zazhi 2000; 8: 196-202
11. Chen KN, Cheng BC, Shi XT, Ma JS. The diagnosis and treatment for recurrent dysphagia of esophageal carcinoma after radical radiotherapy. Chin J Cancer Res 1998; 10: 71-73
12. Chen KN, Zhang LJ, Shi XT, Cheng BC, Xu GW. The advances in molecular biology for esophageal cancer. Zhongguo Xiongxin Xueguan Waike Linchuang Zazhi 1999; 6: 57-60
13. Yamashita K, Mori M, Kataota A, Inoue H, Sugimachi K. The clinical significance of MMP-1 expression in oesophageal carcinoma. Br J Cancer 2001; 84: 276-282
14. Polette M, Nawrocki-Raby B, Gilles C, Clavel C, Birembaut P. Tumour invasion and matrix metalloproteinase. Crit Rev Oncol Hematol 2004; 49: 179-186
15. Kim J, Yu W, Kovalski K, Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 1998; 94: 353-362
16. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737-744
17. Etoh T, Inoue H, Yoshikawa Y, Barnard GF, Kitano S, Mori M. Increased expression of collagenase-3 (MMP-13) and MT1-MMP in oesophageal cancer is related to cancer aggressiveness. Gut 2000; 47: 50-56
18. Chen KN, Xing HP, Cheng BC, Shi XT, Feng RQ. Expression of mdr-1 gene in cancer tissue and its association with morphological indexes of esophageal carcinoma in Anyang. Chin J Cancer Res 1997; 9: 41-44
19. Macaulay VM, O'Byrne KJ, Saunders MP, Braybrooke JP, Long L, Gleeson F, Mason CS, Harris AL, Brown P, Talbot DC. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 1999; 5: 513-520
20. Wylie S, MacDonald IC, Varghese HJ, Schmidt EE, Morris VL, Groom AC, Chambers AF. The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells. Clin Exp Metast 1999; 17: 111-117
21. Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkila P, Kantor C, Gahmberg CG, Salo T, Konttinen YT, Sorsa T, Ruoslahti E, Pasqualini R. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 1999; 17: 768-774